Premium
Lupus Anticoagulant Activity as a Thrombosis Risk Factor in Lung Adenocarcinoma Patients
Author(s) -
DE MEIS ERNESTO,
PINHEIRO VERA R.,
LOURES MARIA APARECIDA L.,
KOTOUC MARIA MERCEDES,
ZAMBONI MAURO M.,
GUEDES MARIA TEREZA S.,
BARROS AILCE S.,
CASTILHO ILDA AKEMI M.,
LEVY ROGER A.
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1381.006
Subject(s) - lupus anticoagulant , medicine , thrombosis , risk factor , lung , adenocarcinoma , gastroenterology , oncology , cancer
There is a high incidence of thrombosis in cancer patients. Retrospective studies indicate that lupus anticoagulant (LA) antibodies can be a thrombosis risk factor in cancer. In 77 patients with different forms of cancer LA and thrombosis incidence were retrospectively evaluated. In a prospective study, with 42 lung adenocarcinoma patients, we measured plasma LA, fibrinogen, factor VIII (FVIII), and thrombosis incidence. A high frequency of LA and thrombosis were observed in both studies. In isolation LA, increased levels of FVIII and fibrinogen could not be considered good markers for the development of thrombosis.